Evidence map›Paper›PMID 36074486›Full record

ArticleJAMA internal medicine2022

COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.

Fiona P Havers, Huong Pham, Christopher A Taylor, Michael Whitaker, Kadam Patel, Onika Anglin, Anita K Kambhampati, Jennifer Milucky, Elizabeth Zell, Heidi L Moline and 31 more

Open access · hybridAbstract read
In one paragraph

Article in JAMA internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 2 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  3. The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
    Trial
  4. Trial
  5. Prolonged higher dose methylprednisoloneThe European respiratory journal · 2023
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 17 institutions in 1 country.

Fiona P HaversUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Huong PhamUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Christopher A TaylorUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Michael WhitakerUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Kadam PatelUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Onika AnglinUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Anita K KambhampatiUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Jennifer MiluckyUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Elizabeth ZellUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Heidi L MolineUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Shua J ChaiField Services Branch, Division of State and Local Readiness, Center for Preparedness and Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Pam Daily KirleyCalifornia Emerging Infections Program, Oakland.
Nisha B AldenColorado Department of Public Health and Environment, Denver.
Isaac ArmisteadColorado Department of Public Health and Environment, Denver.
Kimberly Yousey-HindesConnecticut Emerging Infections Program, Yale School of Public Health, New Haven.
James MeekConnecticut Emerging Infections Program, Yale School of Public Health, New Haven.
Kyle P OpenoDivision of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia.
Evan J AndersonGeorgia Emerging Infections Program, Georgia Department of Public Health, Atlanta.
Libby ReegMichigan Department of Health and Human Services, Lansing.
Alexander KohrmanMichigan Department of Health and Human Services, Lansing.
Ruth LynfieldMinnesota Department of Health, St. Paul.
Kathryn Como-SabettiMinnesota Department of Health, St. Paul.
Elizabeth M DavisNew Mexico Department of Health, Santa Fe.
Cory ClineNew Mexico Department of Health, Santa Fe.
Alison MuseNew York State Department of Health, Albany.
Grant BarneyNew York State Department of Health, Albany.
Sophrena BusheyUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Christina B FelsenUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Laurie M BillingOhio Department of Health, Columbus.
Eli ShiltzOhio Department of Health, Columbus.
Melissa SuttonPublic Health Division, Oregon Health Authority, Portland.
Nasreen AbdullahPublic Health Division, Oregon Health Authority, Portland.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee.
William SchaffnerVanderbilt University Medical Center, Nashville, Tennessee.
Mary HillSalt Lake County Health Department, Salt Lake City, Utah.
Andrea GeorgeSalt Lake County Health Department, Salt Lake City, Utah.
Aron J HallUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Stephanie R BialekUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Neil C MurthyUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Bhavini Patel MurthyUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Meredith McMorrowUS Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia.
Centers for Disease Control and Prevention · USColorado Department of Public Health and Environment · USLake County · USMichigan Department of Health and Human Services · USMinnesota Department of Health · USNew Mexico Department of Health · USNew York State Department of Health · USOhio Department of Health · USOregon Health Authority · USUnited States Public Health Service Commissioned Officers Association · USUniversity of Rochester · USVanderbilt University Medical Center · USEmory University · USGeneral Dynamics (United States) · USGeorgia Department of Public Health · USIbis Reproductive Health · USOffice of Readiness and Response · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Importance: Understanding risk factors for hospitalization in vaccinated persons and the association of COVID-19 vaccines with hospitalization rates is critical for public health efforts to control COVID-19. Objective: To determine characteristics of COVID-19-associated hospitalizations among vaccinated persons and comparative hospitalization rates in unvaccinated and vaccinated persons. Design, Setting, and Participants: From January 1, 2021, to April 30, 2022, patients 18 years or older with laboratory-confirmed SARS-CoV-2 infection were identified from more than 250 hospitals in the population-based COVID-19-Associated Hospitalization Surveillance Network. State immunization information system data were linked to cases, and the vaccination coverage data of the defined catchment population were used to compare hospitalization rates in unvaccinated and vaccinated individuals. Vaccinated and unvaccinated patient characteristics were compared in a representative sample with detailed medical record review; unweighted case counts and weighted percentages were calculated. Exposures: Laboratory-confirmed COVID-19-associated hospitalization, defined as a positive SARS-CoV-2 test result within 14 days before or during hospitalization. Main Outcomes and Measures: COVID-19-associated hospitalization rates among vaccinated vs unvaccinated persons and factors associated with COVID-19-associated hospitalization in vaccinated persons were assessed. Results: Using representative data from 192 509 hospitalizations (see Table 1 for demographic information), monthly COVID-19-associated hospitalization rates ranged from 3.5 times to 17.7 times higher in unvaccinated persons than vaccinated persons regardless of booster dose status. From January to April 2022, when the Omicron variant was predominant, hospitalization rates were 10.5 times higher in unvaccinated persons and 2.5 times higher in vaccinated persons with no booster dose, respectively, compared with those who had received a booster dose. Among sampled cases, vaccinated hospitalized patients with COVID-19 were older than those who were unvaccinated (median [IQR] age, 70 [58-80] years vs 58 [46-70] years, respectively; P < .001) and more likely to have 3 or more underlying medical conditions (1926 [77.8%] vs 4124 [51.6%], respectively; P < .001). Conclusions and Relevance: In this cross-sectional study of US adults hospitalized with COVID-19, unvaccinated adults were more likely to be hospitalized compared with vaccinated adults; hospitalization rates were lowest in those who had received a booster dose. Hospitalized vaccinated persons were older and more likely to have 3 or more underlying medical conditions and be long-term care facility residents compared with hospitalized unvaccinated persons. The study results suggest that clinicians and public health practitioners should continue to promote vaccination with all recommended doses for eligible persons.

Indexed as

COVID-19Influenza VaccinesAdultAgedCOVID-19 VaccinesCross-Sectional StudiesHospitalizationHumansSARS-CoV-2COVID-19 VaccinesInfluenza Vaccines

Identifiers

PMID36074486
PMCPMC9459904
OpenAlexW4294958301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.